Advance reports: ERS

TONADO study: lung function benefits Further lung function and quality of life benefits with tiotropium + olodaterol Respimat® fixed dose combination in COPD were presented recently at the European Respiratory Society (ERS) International Congress in Munich. The 52-week studies, involving more than 5,000 patients with Chronic Obstructive Pulmonary Disease (COPD), showed that tiotropium + olodaterol Respimat® FDC gave further lung function and quality of life benefits to patients, compared to either compound alone.Data also showed that tiotropium + olodaterol Respimat® FDC was well tolerated with a favourable safety profile that was similar to tiotropium or olodaterol alone. The TONADO results,